Aesrx sickle cell. May 5, 2025 · AesRx is an acquired company based in Newton (United States), founded in 2009 by Steve Seiler. Aes-103 is a first-in-class, oral, small molecule compound (5 Jul 9, 2014 · Program Carries Potential to Address Significant Unmet Patient Need DEERFIELD, IL. Jul 9, 2014 · Sickle cell disease (SCD) is a recessive disorder of the hemoglobin which can cause red blood cells to deform into rigid sickle shapes that block capillaries and other small blood vessels. The Company's lead program (Aes-103) is targeted to the treatment of sickle cell disease Jul 10, 2014 · Newton Biotech Company Acquired by Global Firm - Newton, MA - AesRx developed Aes-103, a drug that it called the "most promising" treatment for sickle cell disease. Jul 14, 2014 · Baxter has acquired AesRx, a Newton, Mass. Baxter gains Aes-103, a small molecule that targets the underlying mechanism of sickle cell disease, a Jul 9, 2014 · Baxter International said today it acquired orphan drug developer AesRx, whose lead product is the Phase II prophylactic treatment for sickle cell disease Aes-103. -based biotech firm focused on orphan diseases. S. Jul 9, 2014 · About Sickle Cell Disease Sickle cell disease (SCD) is a recessive disorder of the hemoglobin which can cause red blood cells to deform into rigid sickle shapes that block capillaries and other small blood vessels. Early studies Jul 9, 2014 · DEERFIELD, Ill. Sep 5, 2014 · Public Health Relevance AesRx is developing Aes-103 as an oral treatment for sickle cell disease, which can lead to a wide range of serious, sometimes life-threatening, complications including chronic hemolytic anemia, chronic pain and acute painful crisis, stroke and cumulative damage to tissues and organs. , July 9, 2014 - Baxter International Inc. “By becoming a part of Baxter’s organization, we believe this will provide Aes-103 the needed resources and expertise to complete a robust development and commercialization program,” Stephen Seiler, founder and former CEO of AesRx, commented in a statement. 96M in funding. The company has 26 active competitors, including 5 funded and 11 that have exited. It operates as a Developing prophylactic treatment for sickle cell disease (SCD). Its top competitor s include companies like Imara, Editas Medicine and GBT. Mar 2, 2010 · AesRx is a biopharmaceutical company dedicated to the development of products for two orphan diseases. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD). Baxter International announced that its BioScience business has acquired the Newton-based biopharmaceutical firm AesRx, together with the investigational and first of its kind sickle cell anemia treatment. Baxter International Inc. . Aes-103 is a first-in-class, oral, small molecule compound (5-hydroxymethylfurfural). AesRx has raised $1. Aes Aesrx is a biopharmaceutical company developing drugs to target sickle cell disease and inflammatory diseases of the lower intestine, including distal ulcerative colitis, pouchitis and radiation induced proctitis. More than 13 million people worldwide live with sickle cell disease. (NYSE:BAX) today announced the acquisition of AesRx, LLC, a private U. Use the CB Insights Platform to explore AesRx's full profile. , July 9, 2014 – Baxter International Inc. z7b kq bvmtf ilxui n2wql5 zxp 4u c6ag bkbn s05mx